Posted by Michael Wonder on 16 Jun 2017
Combination treatment Tafinlar (dabrafenib) plus Mekinist (trametinib) approved by Health Canada to treat BRAF V600-positive metastatic non-small cell lung cancer after prior systemic therapy
15 June 2017 - Only approved targeted therapy combination for patients with BRAF V600-positive NSCLC.
A combination oral drug treatment from Novartis has been approved by Health Canada to treat a form of non-small cell lung cancer (NSCLC). Tafinlar (dabrafenib) in combination with Mekinist (trametinib) has been approved for the treatment of patients with metastatic NSCLC with a BRAF V600 mutation whose disease has progressed following systemic therapy.
It is estimated that about 1-3% of Canadians with NSCLC are BRAF V600-positive, a population who previously had few treatment options.
